Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2003
10/01/2003CN1444934A Method for eliminating strange smell of oral medicine of L-arginine
10/01/2003CN1444933A Ethylenediamine Diaceturate injection
10/01/2003CN1444932A Application of all transconfiguration retinoic acid in preparing weight reduction medicine
10/01/2003CN1444931A Aceglutamide injection
10/01/2003CN1444930A New usage of agmatine
10/01/2003CN1444929A Fibrauretine dispersant tablet and its preparing method
10/01/2003CN1444928A Drop pills of five esters and its preparing method
10/01/2003CN1444926A Bio-adhesiveness drug release system
10/01/2003CN1444922A Application of biologically active substance-fenugreek ketone and its derivatives
10/01/2003CN1444872A Products using L-arginine as raw materials
10/01/2003CN1122670C Thiazolobenzoheterocycles, prepn method and medicines containing same
10/01/2003CN1122669C Novel 8H thiophene [2,3-b] pyrrolinezine-8-on compound, its preparing method and their medicinal compounds containing them
10/01/2003CN1122668C Epothilone derivatives and their preparation method and their use as antitumor agents
10/01/2003CN1122667C Process for preparing N6-substituted deaza adenosine derivatives
10/01/2003CN1122666C New 2,3-dioxide indanol compounds, process for their preparation and pharmaceutical compositions containing them
10/01/2003CN1122662C Arylsulfonylamino hydroxamic acid derivatives
10/01/2003CN1122657C Colchicine skeleton compounds, their use as medicaments and compounds containing them
10/01/2003CN1122534C Method for reducing side effects of drug
10/01/2003CN1122528C Compound safflower oil preparation and medicine containing it
10/01/2003CN1122521C Coptis liquid for relieving inflammation and moistening skin and its preparing process
10/01/2003CN1122516C Medicine for treating oral and throat disease
10/01/2003CN1122514C Minocycline vaginal powder
10/01/2003CN1122513C Use of compound in medicine for preparation of inhibiting pathological conditions
10/01/2003CN1122512C External use medicine composition for promoting blood circulation to stop pain
10/01/2003CN1122511C Nutrient agent and its application
10/01/2003CN1122510C Medicinal composition for treating AIDS and its application
10/01/2003CN1122456C Food and vitamin products containing natural isomer of reduced folates
10/01/2003CN1122443C Antiparasitic composition for treating and protecting pets
09/2003
09/30/2003US6627774 N-deacetylthiocolchicine derivatives and pharmaceutical compositions containing them
09/30/2003US6627754 Pyrrolo[2,3-d]pyrimidine compounds
09/30/2003US6627743 6-O-methylerythromycin A crystal form III
09/30/2003US6627738 No-modified hemoglobins and uses therefor
09/30/2003US6627730 Of given amino acid sequence, and diagnostic test kit; multidrug resistance
09/30/2003US6627664 Administering perylenequinone derivative, and activating the derivative by exposing the perylenequinone to sound of a pre-determined frequency for therapy
09/30/2003US6627663 Especially medicaments containing verapamil; a lecithin/isopropyl myristate solution; butylated hydroxy toluene; pluronic F127; an antioxidant agent suspended in a carrier
09/30/2003US6627662 3-amino-propoxyphenyl derivatives (I)
09/30/2003US6627661 Use of 5HT-6 antagonists
09/30/2003US6627660 Stabilized thyroxine compounds
09/30/2003US6627659 Methods of decreasing the effects of oxidative stress in patients undergoing hemodialysis by intravenously administering N-acetylcysteine or a pharmaceutically acceptable salt thereof to the patient.
09/30/2003US6627658 Administration of an effective amount of 15-epi-16-(para-fluoro)-phenoxy-lipoxin A4, Lipoxin-A4, 15-epi-lipoxin4 or 15-R/S-methyl-lipoxin4 or salts, esters, amides, carboxylic acids or prodrugs to treat angiogenesis
09/30/2003US6627656 Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore
09/30/2003US6627655 Vanadium (IV) metallocene complexes having spermicidal activity
09/30/2003US6627653 Anticonvulsant derivatives useful for the treatment of depression
09/30/2003US6627652 Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
09/30/2003US6627651 Exhibiting preventive and therapeutic effects against HIV infectious diseases wherein R1 is an optionally substituted five- or six-membered ring group; X1 is a free valency or the like; W is a divalent group and inhibitors of HIV (human
09/30/2003US6627650 An isomer thereof, or an addition salt thereof with a pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful as anti- cancer agents.
09/30/2003US6627649 (2S)-1-((2R,3S)-5-chloro-3-(2-chlorophenyl)-1-(3,4 -dimethoxybenzenesulfonyl)-3-hydroxy-2,3-dihydro-1H-indole-2 -carbonyl)pyrrolidine-2-carboxamide, a selective V1a arginine vasopressin receptor antagonist, in combination with the
09/30/2003US6627645 Muscarinic agonists
09/30/2003US6627644 4-piperidinyl alkyl amine derivatives as muscarinic receptor antagonists
09/30/2003US6627643 Sodium-hydrogen exchanger type 1 (NHE-1) inhibitors of formula I' are useful for the prevention and treatment of myocardial ischemic injury. Myocardial ischemic injury can occur in out-patient in perioperative settings and can lead to sudden
09/30/2003US6627642 Solved by the present invention is to provide a quinolinone derivative formulation, and its production method, having for its active ingredient the beta crystal form and/or gamma crystal form of the quinolinone derivative represented with
09/30/2003US6627641 Antimalarial naphthylisoquinoline alkaloid derivatives, methods for obtaining such derivatives, and methods of using such antimalarial compounds for the prevention of malaria infections in mammals and for treating mammals with malarial
09/30/2003US6627640 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
09/30/2003US6627638 Viricides, anticarcinogneic agents
09/30/2003US6627637 I kappa B kinase inhibitors for treating various disorders including arthritis
09/30/2003US6627635 Method of preventing abuse of opioid dosage forms
09/30/2003US6627633 The compounds also are potent inhibitors of human cellular proliferation. As such, the compounds constitute pharmaceutical compositions with a pharmaceutically acceptable carrier. Such compounds are useful in inhibiting cellular
09/30/2003US6627632 Compositions and methods for the treatment of anorectal disorders
09/30/2003US6627631 Desoxypeganine and its pharmaceutically acceptable acid addition salts can be used in the treatment of alcoholism. Said substances are administered preferably in a continuous and controlled manner. The pharmaceutical administration form
09/30/2003US6627629 Useful for the treatment or prevention of asthma and other allergic diseases.
09/30/2003US6627628 Cardiovascular diseases such as hypertension, angina pectoris, heart failure, thrombosis and atherosclerosis. The compounds of formula (I) are able to modulate the body's own production of cyclic guanosine monophosphate (cGMP) and are suitable for
09/30/2003US6627627 Aralkyl and aralkylidene heterocyclic lactams and imides
09/30/2003US6627626 Antiinflammation agents and antiarthritic agents colon cancer, and Alzheimer's disease in mammals, preferably humans, dogs, cats and livestock animals.
09/30/2003US6627625 Beta-lactam antibiotics and beta -lactamase inhibitors provides significant neurotropic effects in warm-blooded vertebrates evidenced inter by anxiolytic and antiaggressive behavior modification ans enhanced cognition
09/30/2003US6627623 Induction apoptosis
09/30/2003US6627622 (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
09/30/2003US6627621 Neutrophil function inhibitors
09/30/2003US6627620 Composition set and kit for use in intraocular surgery
09/30/2003US6627616 Intravascular delivery of non-viral nucleic acid
09/30/2003US6627614 Treating a patient having a disease associated with undesirable or uncontrolled cell proliferation. The method comprises: administering to the patient an anthracycline for a period of time during which a 20(S)-camptothecin is not
09/30/2003US6627613 Application of water and organic solvent soluble ivermectin for topical and oral use
09/30/2003US6627610 Treat a viral infection in a subject via inhibiting the prenylation of a protein contained in the virus infecting said subject, which method comprises administering to said subject an agent selected from the group consisting of amino
09/30/2003US6627605 Polynucleotides which encode them, and methods for their use. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention further provides methods for diagnosing or treating disorders with
09/30/2003US6627602 Preventing desensitization of receptors
09/30/2003US6627231 Protecting cell from damage caused by free radicals by administering lipophilic antioxidant comprising vitamin E, beta carotene, extract of Lycopersicum esculentum, hydrophilic antioxidant comprising vitamin c, extract of vitis vinifera
09/30/2003US6627224 Low dose entecavir formulation and use
09/30/2003US6627223 Timed pulsatile drug delivery systems
09/30/2003US6627222 Amoxicillin-dicloxacillin antibiotic composition
09/30/2003US6627221 Unit dose containing less than 5% by weight of stearic acid lubricant in the outer phase, relative to the total weight have good dissolution rate, heat resistance and storage stability for drugs such as ibandronate sodium
09/30/2003US6627219 Oily capsule preparation and the method for preparing same
09/30/2003US6627215 Devices for improved wound management
09/30/2003US6627214 Adding fumaric acid to reduce throat burn sensation
09/30/2003US6627213 Administering on the same day the infant is fed human breast milk a supplement free of carbohydrate and comprising casein, salts of casein, whey, and casein hydrolysates; decrease of jaundice and increase of excretion of bilirubin
09/30/2003US6627212 Containing titanium dioxide platelets
09/30/2003US6627211 Vehicle containing alcohol, glycol and biological surfactant
09/30/2003US6627210 Alpha-2-adrenergic agonist component is selected from the group consisting of imino-imidazolines, imidazolines, imidazoles, azepines, thiazines, oxazolines, guanidines, catecholamines and derivatives or mixtures
09/30/2003US6627209 Implanting stent having biodegradable carrier coating and calcium channel blocker
09/30/2003US6627204 Polynucleotides and polypeptides BASB033 from neisseria meningitidis and their uses
09/30/2003US6627196 Dosages for treatment with anti-ErbB2 antibodies
09/30/2003US6627088 Depth-type filter for killing microorganisms and inactivating viruses and its use
09/30/2003US6626932 Therapeutic light source and method
09/30/2003CA2393614C Antibacterial clarithromycin compositions and processes for making the same
09/30/2003CA2279796C Process for the preparation of substituted pyridines
09/30/2003CA2254750C Inhibition of matrix metalloproteases by 2-(.omega.-aroylalkyl)-4-biaryl-oxobutyric acids
09/30/2003CA2245768C Methods for treating emesis and central nervous system disorders using optically pure (+) norcisapride
09/30/2003CA2133759C Evaluation and treatment of patients with progressive immunosuppression
09/30/2003CA2123321C Combination chemotherapy
09/30/2003CA2114630C Steroid sulphatase inhibitors
09/30/2003CA2112982C Process for the preparation of optical isomers of a amino-2-napththyridine derivative
09/30/2003CA2112980C Process for the preparation of the dextrogyral isomer of a isoindolinone derivative
1 ... 5327 5328 5329 5330 5331 5332 5333 5334 5335 5336 5337 5338 5339 5340 5341 5342 5343 5344 5345 5346 5347 ... 7860